Published in J Rheumatol on February 15, 2010
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet (2011) 5.56
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet (2010) 3.58
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet (2010) 2.44
The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum (2013) 2.40
Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol (2003) 2.30
Nucleus pulposus notochord cells secrete connective tissue growth factor and up-regulate proteoglycan expression by intervertebral disc chondrocytes. Arthritis Rheum (2006) 2.15
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Investigating the genetic association between ERAP1 and ankylosing spondylitis. Hum Mol Genet (2009) 1.95
Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol (2003) 1.85
Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum (2005) 1.71
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis (2011) 1.68
Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol (2005) 1.62
Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2007) 1.56
Notochord cells regulate intervertebral disc chondrocyte proteoglycan production and cell proliferation. Spine (Phila Pa 1976) (2006) 1.49
Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality: A Population-Based Study. Ann Intern Med (2015) 1.49
Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol (2010) 1.48
Association of an ERAP1 ERAP2 haplotype with familial ankylosing spondylitis. Ann Rheum Dis (2009) 1.42
An i2b2-based, generalizable, open source, self-scaling chronic disease registry. J Am Med Inform Assoc (2012) 1.39
Common aspects of human and primate seronegative arthritis. J Rheumatol (2004) 1.39
Endoplasmic reticulum aminopeptidases: Biology and pathogenic potential. Nat Rev Rheumatol (2010) 1.39
Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum (2008) 1.38
Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis (2011) 1.35
Quantitative pupillometry, a new technology: normative data and preliminary observations in patients with acute head injury. Technical note. J Neurosurg (2003) 1.32
ASsessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum (2005) 1.28
Differential role of actin, clathrin, and dynamin in Fc gamma receptor-mediated endocytosis and phagocytosis. J Biol Chem (2002) 1.27
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis (2011) 1.21
Notochordal cells protect nucleus pulposus cells from degradation and apoptosis: implications for the mechanisms of intervertebral disc degeneration. Arthritis Res Ther (2011) 1.19
Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum (2005) 1.17
Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series. Rheumatology (Oxford) (2009) 1.13
Pathogenesis of ankylosing spondylitis and reactive arthritis. Curr Opin Rheumatol (2005) 1.12
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol (2007) 1.11
The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. J Rheumatol (2004) 1.10
Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum (2005) 1.09
ARTS1 polymorphisms are associated with ankylosing spondylitis in Koreans. Ann Rheum Dis (2009) 1.09
Immunodominance: a pivotal principle in host response to viral infections. Clin Immunol (2012) 1.08
Association of interleukin 23 receptor variants with psoriatic arthritis. J Rheumatol (2009) 1.06
Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther (2006) 1.06
Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-gamma dysregulation. Arthritis Rheum (2008) 1.06
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. J Rheumatol (2007) 1.04
Serum cytokine receptors in ankylosing spondylitis: relationship to inflammatory markers and endoplasmic reticulum aminopeptidase polymorphisms. J Rheumatol (2010) 1.03
Genetic studies in familial ankylosing spondylitis susceptibility. Arthritis Rheum (2004) 1.03
Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases? J Rheumatol (2013) 1.02
Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol (2015) 1.02
Endoplasmic reticulum aminopeptidase 1 (ERAP1) exhibits functionally significant interaction with HLA-B27 and relates to subtype specificity in ankylosing spondylitis. Ann Rheum Dis (2012) 1.01
Accumulation of diacylglycerol in the Chlamydia inclusion vacuole: possible role in the inhibition of host cell apoptosis. J Biol Chem (2005) 1.01
Genetic studies of ankylosing spondylitis in Koreans confirm associations with ERAP1 and 2p15 reported in white patients. J Rheumatol (2010) 1.01
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol (2009) 1.00
Radiographic severity of ankylosing spondylitis is associated with polymorphism of the large multifunctional peptidase 2 gene in the Spondyloarthritis Research Consortium of Canada cohort. Arthritis Rheum (2011) 1.00
Development and validation of a case ascertainment tool for ankylosing spondylitis. Arthritis Care Res (Hoboken) (2010) 0.99
ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther (2005) 0.97
Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol (2008) 0.96
Modulation of Mac-1 (CD11b/CD18)-mediated adhesion by the leukocyte-specific protein 1 is key to its role in neutrophil polarization and chemotaxis. J Immunol (2002) 0.96
Toll-like receptor 2 variants are associated with acute reactive arthritis. Arthritis Rheum (2008) 0.96
Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol (2010) 0.96
Molecular and cellular biology of new bone formation: insights into the ankylosis of ankylosing spondylitis. Curr Opin Rheumatol (2003) 0.95
The molecular basis of complete complement C4A and C4B deficiencies in a systemic lupus erythematosus patient with homozygous C4A and C4B mutant genes. J Immunol (2002) 0.93
Novel genetic markers in the 5'-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum (2003) 0.93
Innate immunity and arthritis: neutrophil Rac and toll-like receptor 4 expression define outcomes in infection-triggered arthritis. Arthritis Rheum (2005) 0.92
Infectious complications of biological therapy. Curr Opin Rheumatol (2009) 0.92
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol (2009) 0.91
Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. Arthritis Rheum (2005) 0.90
The chromosome 16q region associated with ankylosing spondylitis includes the candidate gene tumour necrosis factor receptor type 1-associated death domain (TRADD). Ann Rheum Dis (2009) 0.90
Intervertebral disc-derived stem cells: implications for regenerative medicine and neural repair. Spine (Phila Pa 1976) (2013) 0.90
Recent advances in the treatment of the spondyloarthropathies. Curr Opin Rheumatol (2004) 0.90
Symptomatic acute reactive arthritis after an outbreak of salmonella. J Rheumatol (2008) 0.90
The regenerative capacity of the notochordal cell: tissue constructs generated in vitro under hypoxic conditions. J Neurosurg Spine (2009) 0.89
Validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging spinal inflammation index: is it necessary to score the entire spine? Arthritis Rheum (2007) 0.89
RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther (2010) 0.88
NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms? Ann Rheum Dis (2012) 0.88
Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. J Transl Med (2012) 0.88
Neuropathic pain in ankylosing spondylitis: a psychophysics and brain imaging study. Arthritis Rheum (2013) 0.88
IL-23R polymorphisms in patients with ankylosing spondylitis in Korea. J Rheumatol (2009) 0.87
Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum (2006) 0.86
The Spondyloarthritis Research Consortium of Canada registry for spondyloarthritis. J Rheumatol (2011) 0.86
Reactive arthritis: developments and challenges in diagnosis and treatment. Curr Rheumatol Rep (2012) 0.86
Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo-controlled study. Arthritis Care Res (Hoboken) (2012) 0.86
Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis. Int Immunol (2009) 0.85
Interleukin 1 and nuclear factor-kappaB polymorphisms in ankylosing spondylitis in Canada and Korea. J Rheumatol (2005) 0.85
Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheum (2006) 0.85
Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). Rheumatology (Oxford) (2012) 0.85
Chlamydia and chronic arthritis. Ann Med (2011) 0.84
Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Care Res (Hoboken) (2010) 0.84
Postural control is altered in patients with ankylosing spondylitis. Clin Biomech (Bristol, Avon) (2011) 0.83
Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol (2010) 0.83
Chlamydia-induced ReA: immune imbalances and persistent pathogens. Nat Rev Rheumatol (2011) 0.83
Antigen-specific therapy of rheumatoid arthritis. Expert Opin Biol Ther (2008) 0.83
Intracellular survival and persistence of Chlamydia muridarum is determined by macrophage polarization. PLoS One (2013) 0.83